Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
yttrium Y 90-edotreotide · 2 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| yttrium Y 90-edotreotide | RADIATION | - |
DISEASE CHARACTERISTICS: Histologically confirmed small cell lung cancer Must have received one prior chemotherapy regimen and relapsed OR Diagnosis of metastatic breast cancer No more than two prior chemotherapy regimens for metastatic disease Measurable disease Prior radiotherapy to measurable les...
Top 20 of 87 competitors
Yttrium Y 90-edotreotide is an investigational radiopharmaceutical being studied for the treatment of brain and central nervous system tumors and breast cancer. It is also being evaluated in other cancer types, including gastrointestinal carcinoid tumors, islet cell tumors, lung cancer, lymphoma, and melanoma. It is not yet approved and remains in clinical development.
Yttrium Y 90-edotreotide is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with various cancers.
Yttrium Y 90-edotreotide is in Phase 1 clinical development. One Phase 1 trial has been completed, and a Phase 2 trial has also been completed. The drug is investigational and has not received FDA approval.
Yttrium Y 90-edotreotide has been studied in two completed clinical trials. NCT00006368 was a Phase 1 trial in patients with refractory or recurrent cancer, enrolling 60 participants. NCT00006370 was a Phase 2 trial in patients with refractory small cell lung cancer or metastatic breast cancer, enrolling 275 participants.
Yes, yttrium Y 90-edotreotide is also known as radiolabeled SMT-487, specifically yttrium Y 90-DOTA-tyr3-octreotide. The Phase 2 trial NCT00006370 used this alternative name to describe the same drug being studied in patients with refractory small cell lung cancer or metastatic breast cancer.